TEM
$50.84
Tempus AI, Inc.
Recent News
Is Tempus AI (TEM) The Best AI Healthcare Stock in Cathie Wood’s Portfolio?
Tempus AI (NASDAQ:TEM) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Tempus AI (NASDAQ:TEM) uses AI to analyze and process large datasets to find patterns that help doctors treat patients more efficiently. ARK increased its stake in Tempus AI (NASDAQ:TEM) by 6% in the fourth quarter to about $446.28 million. […]
Tempus AI Expands Clinical Validation of AI-Powered Cancer Diagnostics
TEM advances precision oncology as studies validate IPS, PurIST and xF+ diagnostics, highlighting stronger guidance for cancer therapy and biomarker detection.
Assessing Tempus AI (TEM) Valuation After Expanded Merck Collaboration Announcement
Tempus AI (TEM) is back in focus after announcing an expanded multi year collaboration with Merck that puts its de identified multimodal data and AI tools to work on Merck’s oncology and broader drug discovery efforts. See our latest analysis for Tempus AI. Despite the Merck collaboration and the February earnings and guidance update, momentum in Tempus AI’s share price has been weak. The 90 day share price return shows a decline of 32.17% and the year to date share price return shows a...
Tempus AI Deepens Merck Collaboration As Pharma Demand And Losses Evolve
Tempus AI and Merck announced an expanded multi year collaboration focused on AI driven precision medicine and drug discovery in oncology and other therapeutic areas. The partnership aims to combine Tempus AI's large scale genomic and clinical data with Merck's drug development capabilities to support biomarker discovery and clinical research. The agreement extends and broadens an existing relationship, positioning Tempus AI as a key data and AI partner for a major pharmaceutical...
Tempus AI, Inc. (TEM) Announces Strategic Deal with Merck to Fast-Track AI-Driven Precision Medicine
Tempus AI, Inc. (NASDAQ:TEM) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026. On March 3, the company announced a strategic partnership with Merck to fast-track the development of AI-driven precision medicine and support the pharma-maker’s oncology portfolio and other therapeutic offerings. As part of the agreement, Merck will leverage Tempus […]